摘要
目的:探讨非那雄胺对抗栓治疗的BPH患者继发肉眼血尿的治疗。方法:2006年9月～2007年2月明确诊断为BPH继发肉眼血尿的患者105例,分为抗栓组(81例)和对照组(24例)。抗栓组采用抗栓治疗联合非那雄胺,对照组仅采用非那雄胺治疗,随访6个月比较血尿的治疗结果。结果:抗栓组肉眼血尿完全消失52例(64.2%),血尿消失平均时间3.9周(1～6周);血尿较治疗前减轻者12例(14.8%)。对照组肉眼血尿完全消失16例(66.7%),平均时间3.2周(1～5周);血尿较治疗前减轻者4例(16.7%)。抗栓组肉眼血尿消失的平均时间长于对照组(P<0.05),两组之间在血尿治愈率(血尿消失)和有效率(血尿消失+血尿减轻)方面无显著差异,服用不同种类抗栓药物的患者间血尿治愈率无显著差异。结论:对于使用抗栓药物治疗的BPH患者继发肉眼血尿,口服非那雄胺是一种有效的治疗方法,治愈率和有效率与未抗栓治疗组接近,但治愈血尿所用的时间略长。
Objective ： To study the effect of finasteride on benign prostatic hyperplasia （BPH） related gross hematuria in patients receiving anticoagulant. Methods ： A total of 105 patients with BPH related gross hematuria were divided into an anticoagulant group （ n = 81 ） , treated with combined therapy of anticoagulants and finasteride, and a control group （ n = 24） , given finasteride only at 5 mg daily. The therapeutic effects were compared by a 6-month follow-up. Results ： In the anticoagulant group, gross hematuria was cured in 52 patients （64.2%）, taking an average time of 3.9 weeks （ 1-6 weeks）, and improved in 12 patients （ 14.8% ）, as compared with 16 patients cured （66.7%）, 3.2 weeks taken （ 1-5 weeks）, and 4 patients improved （ 16.7% ） in the control group. The mean time taken to resolve hematuria was longer in the former （ P 〈 0.05 ）. But the cure rates had no significant differences either between the two groups or among the subgroups receiving different anticoagulants. Conclusion ： Finasteride is an effective therapeutic for BPH related hematuria in patients receiving different anticoagulants. It makes no significant differences in cure and effectiveness rates between patients treated with and without anticoagulant, but takes an average of longer time to resolve hematuria in patients receiving anticoagulant.
出处
《中华男科学杂志》
CAS
CSCD
北大核心
2009年第1期31-33,共3页
National Journal of Andrology
关键词
非那雄胺
良性前列腺增生
血尿
抗栓
finasteride
benign prostatic hyperplasia
hematuria
anticoagulant
